Speaking at the 2017 Biotech Showcase™ in San Francisco, Grünenthal CEO Gabriel Baertschi reveals his ambition to grow the company from its current EUR 1.4 billion a year revenues to EUR 2 billion by 2022, launching four new medicines by that date, consolidating its position as a leader in pain therapeutics, while entering new areas. Consequently, he was at the meeting seeking new opportunities in indications adjacent to pain including inflammation, arthritis, gout, as well as Parkinson’s disease and rare diseases such as Duchenne muscular dystrophy. Looking at both early stage preclinical projects and later stage clinical assets, Baertschi is keen to expand the company’s global footprint. Already with a significant presence in Europe and Latin America, the company wants to expand in the US while entering the Japanese market for the first time
Home » Partnering & Drug Development » Biotech Showcase™ 2017: Grünenthal looks beyond pain for transformative deals
Biotech Showcase™ 2017: Flexion gears up to commercialize Zilretta
Following submission of new drug application of Zilretta (FX006) for knee osteoarthritis in mid-December 20...
Other content in this Stream
BIO-Europe Spring 2017 kicks off this week in Barcelona
Report gives substance to fast-paced scientific discoveries in microbiome
Guest post by Eric de La Fortelle, Venture Partner at Seventure Partners Microbes are everywhere, and apart from the occasional pathogen, they are a positive force for health maintenance. Indeed...
2016 – A Year in Review for Advanced Therapies
Guest post by Patricia Reilly, M.S., Head of Intelligence Alliances and Unification, Pharma Intelligence | Informa The past year saw intensifying dialogue on how to assess the value of and...
Stirring the Pot for Entrepreneurship in European Tech Transfer
Guest post by Luke Timmerman, founder and editor of the Timmerman Report, and a regular contributor to Forbes and STAT News. The science in many parts of Europe is first-rate. No one disputes...
World RARE Disease Day shines a light on rare disease community
Tomorrow is the 10th annual World RARE Disease Day. Various activities are taking place all over the United States as well as countless locations around the world. World RARE Disease Day is an...
Barcelona biotech companies shine light on regional entrepreneurship
Investors are always on the lookout for innovative biotech startups, and the Catalonia, Spain biopharma cluster has plenty to offer in the way of innovation from among its member companies....
Increase the value of your asset: Think with the end in mind
Developing a drug is a very long journey, therefore it is critical to define the destination upfront. The Target Product Profile is like a postcard of your desired destination. It informs the data...
What’s the deal with Immuno-oncology partnering?
Insight wanted to get the lay of the I/O landscape, so who better to speak with than Jeff Bockman, Vice President of Defined Health. Not only was Jeff kind enough to share his insights with us,...
Biotech Showcase™ 2017: Chinese capital accesses Western innovation to create homegrown industry
With the Chinese market growing at 10–15% a year, it is poised to be world’s largest by 2026. Tony Chu, co-founder and managing partner at consultants TPP Healthcare, explains to Mike Ward, global dir
Biotech Showcase™ 2017: Advancing neurokinin receptor antagonists in respiratory and women’s health
Starting the year with a cash injection of GDP 23 million, 2012 GSK spin-out NeRRe Therapeutics intends to advance its neurokinin receptor antagonist pipeline towards late-stage clinical development.
Biotech Showcase™ 2017: Q BioMed plans to accelerate up to four more assets
Established in June 2015, Q BioMed, the NYC-based biomedical acceleration development company, is looking to add three to four more assets to its portfolio. Company founder and CEO, Denis Corin, outli
Biotech Showcase™ 2017: Double-barreled approach doubles survival times in recurrent glioma patients
Brain cancer remains one of the deadliest diseases, and little to no effective treatments exist. Marty Duvall, newly appointed CEO of San Diego-based gene therapy technology company Tocagen, tells Mik
Biotech Showcase™ 2017: Payer environment will impact biopharma prospects in 2017
An increased focus on the need to access and develop truly transformational medicines was a key theme in the hallway chatter at this year’s Biotech Showcase/JP Morgan Healthcare meetings. Michael Hay,
Biotech Showcase™ 2017: Janssen focuses cardiometabolic R&D on prevention, cure and interception
With readouts in important trials of key drugs Invokana and Xarelto on the horizon, Dr. James F. List, Global Therapeutic Area Head of Cardiovascular and Metabolism, has plenty of reasons for insomnia
Biotech Showcase™ 2017: J&J poised to establish no-strings-attached JLABS outside America
As Johnson & Johnson announced the establishment of its eighth JLABS facility, in collaboration with New York State and the New York Genome Center, Melinda Richter, head of Johnson & Johnson Innovatio
Biotech Showcase™ 2017: Reinventing Arena to focus on Phase II clinical candidates
In the six months after joining Arena Pharmaceuticals as CEO, Dr. Amit Munshi has been busy: reducing the company’s commitment to obesity drug Belviq, which it has partnered with Eisai; spinning out t
Biotech Showcase™ 2017: ProNAI defects from oligos to DDR as Sierra Oncology
Sierra Oncology president and CEO Dr. Nick Glover tells Mike Ward, Informa Pharma Intelligence insight global director of content, how the company is rebranding itself from its former incarnation ProN
Biotech Showcase™ 2017: PhaseRx makes more noise than silence with mRNA delivery
Having ditched RNA silencing in 2012, PhaseRx president and CEO Dr. Robert Overell explains to Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, how delivering
Biotech Showcase™ 2017: Second Genome CEO predicts paradigm shift with microbiome discovery
Microbiome discovery and development will trigger the next major paradigm shift in medicine, more profound than the discovery of recombinant DNA, Second Genome CEO Glenn Nedwin predicted in an intervi
Biotech Showcase™ 2017: MEI Pharma rides wave of interest in AML